[Rapport de recherche] La taille du marché des théranostiques radiopharmaceutiques devrait passer de 1 814,58 millions de dollars US en 2022 à 3 441,97 millions de dollars US d'ici 2028 ; on estime qu'il enregistrera un TCAC de 11,3 % de 2022 à 2028.
Le marché du théranostique radiopharmaceutique est segmenté en fonction du type de produit, du radio-isotope, de la source, de l'application, de l'indication, de l'utilisateur final et de la géographie. Le rapport offre des informations et une analyse approfondie du marché, en mettant l'accent sur des paramètres tels que la dynamique, les tendances et les opportunités qui prévalent sur le marché du théranostique radiopharmaceutique. Il fournit également une analyse du paysage concurrentiel des principaux acteurs du marché mondial du théranostic radiopharmaceutique.
Aperçu du marché
L'application croissante dans le traitement des troubles cardiovasculaires stimule la croissance du marché mondial du théranostic radiopharmaceutique
Les maladies cardiovasculaires (MCV) comptent parmi les maladies chroniques les plus répandues au 21e siècle, avec un taux de mortalité élevé. En raison de leur mode de vie sédentaire, les maladies cardiovasculaires sont la principale cause de mortalité et de morbidité dans les pays développés. De plus, l'obésité et le diabète, ainsi que les maladies apparentées, sont associés aux maladies cardiovasculaires et deviennent comorbides. De plus, une complication telle qu'une obstruction de l'artère coronaire est l'une des principales causes de décès chez l'adulte, entraînant une plaque de thrombus dans l'intima de la paroi artérielle, principalement dans l'artère carotide. Selon les données du National Center for Biotechnology, environ 17,7 millions de personnes sont décédées dans le monde en 2015 des suites de maladies cardiovasculaires. À cet égard, on estime que la mortalité due aux maladies cardiovasculaires pourrait atteindre 22 millions d'ici 2030. Les applications thérapeutiques dans les maladies cardiovasculaires comprennent la nanomédecine dans l'angine de poitrine, la myocardite, l'infarctus du myocarde, la maladie péricardique, la thrombose, l'athérosclérose, l'hyperlipidémie, l'hypertension, l'hypertension artérielle pulmonaire, et accident vasculaire cérébral. Les nanomédicaments théranostiques peuvent prolonger la circulation systémique, échapper aux systèmes de défense de l'hôte et délivrer des agents théranostiques au site cible pour l'imagerie et la thérapie aux niveaux cellulaire et moléculaire.
Aperçus stratégiques
Conformément au Selon un rapport de 2022 des Centers for Disease Control and Prevention (CDC), les maladies cardiaques sont l'une des principales causes de décès chez les hommes et les femmes aux États-Unis. Les maladies cardiaques ont été à l'origine d'environ 697 000 décès, soit 1 décès sur 5, aux États-Unis en 2020. Un rapport du National Institute of Health (NIH) indique que les nanoparticules théranostiques ont suscité une attention considérable dans le domaine médical, car les techniques aident à surmonter complexités et complications physiopathologiques associées aux maladies cardiovasculaires. L'imagerie cardiovasculaire des patients atteints d'athérosclérose fournit des preuves physiopathologiques qui peuvent aider à traiter les maladies cardiovasculaires. De plus, les nanoparticules théranostiques peuvent être combinées avec une gamme de techniques d'imagerie, telles que l'imagerie par résonance magnétique (IRM), la tomographie par émission de positrons (PET) et la tomodensitométrie (CT). Diverses études de recherche clinique ont été menées dans des laboratoires cliniques jusqu'à présent. Un complexe thérapeutique trois en un a été construit, en associant une sonde polymérique photoacoustique à des nanoparticules-PLCDP@PMH. Les évaluations cliniques in vivo révèlent que le PLCDP@PMH offre des avantages lucratifs pour l'approche théranostique de la détection précoce de l'athérosclérose chez les patients.
Informations basées sur le type de produit
Basé sur le type de produit , le marché des théranostiques radiopharmaceutiques est segmenté en traceurs de tomographie par émission de positrons (TEP), en émetteurs bêta et en émetteurs alpha. En 2022, le segment des traceurs de tomographie par émission de positrons (TEP) détenait la plus grande part du marché du marché mondial des théranostiques radiopharmaceutiques, et il devrait enregistrer le TCAC le plus élevé au cours de la période de prévision.
Marché des théranostiques radiopharmaceutiques, par type de produit – 2022–2028
(image) Aperçus basés sur les radio-isotopes
Basé sur les radio-isotopes, le marché du théranostic radiopharmaceutique est divisé en Lutétium (Lu) 177, Gallium-68, Iode-131, Iode -123, Technétium-99, Yttrium-90 (Y-90), Cuivre (Cu) 64, 18F, Cuivre (Cu) 67 et autres. En 2022, le segment Lutétium (Lu) 177 détenait la plus grande part de marché du marché mondial des théranostiques radiopharmaceutiques et devrait enregistrer le TCAC le plus élevé au cours de la période de prévision.
Informations basées sur la source
< p>Basé sur la source, le marché du théranostique radiopharmaceutique est divisé en cyclotrons et réacteurs nucléaires. Le segment des cyclotrons détenait une plus grande part du marché en 2022, et il devrait enregistrer à un TCAC plus élevé au cours de la période de prévision.
Application-Based Insights
Basé sur l'application, le marché des théranostiques radiopharmaceutiques est divisé en thérapie ciblée (Rx) et diagnostic compagnon (CDx). En 2022, le segment thérapeutique ciblé (Rx) détenait une plus grande part du marché, et il devrait enregistrer un TCAC plus élevé au cours de la période de prévision.
Indications basées sur les indications
Sur la base des indications, le marché des théranostiques radiopharmaceutiques est segmenté en oncologie, neurologie, cardiologie et autres. Le segment de l'oncologie détenait la plus grande part du marché en 2022, et il devrait enregistrer le TCAC le plus élevé au cours de la période de prévision.
Insights basés sur l'utilisateur final
Basés sur l'utilisateur final , le marché du théranostic radiopharmaceutique est segmenté en hôpitaux, centres d'imagerie diagnostique, instituts universitaires et de recherche, etc. Le segment des hôpitaux détenait la plus grande part de marché en 2022. Cependant, le segment des instituts universitaires et de recherche devrait enregistrer le TCAC le plus élevé au cours de la période de prévision. Les hôpitaux utilisent des systèmes technologiquement avancés pour traiter les anévrismes cardiaques, les anévrismes neurologiques, les tumeurs oncologiques et d'autres affections similaires. La prévalence croissante de diverses maladies et le nombre croissant d'hôpitaux contribuent à la croissance du marché du segment des hôpitaux.
Les acteurs du marché du théranostic radiopharmaceutique adoptent des stratégies organiques, telles que le lancement et l'expansion de produits, pour étendre leur empreinte et portefeuille de produits et répondre aux demandes croissantes. Les stratégies de croissance inorganiques observées sur le marché sont les partenariats et les collaborations. Ces stratégies de croissance ont permis aux acteurs du marché d'étendre leurs activités et de renforcer leur présence géographique. De plus, des acquisitions, des partenariats et d'autres stratégies de croissance les aident à renforcer leur clientèle.
- En octobre 2022, Telix a reçu l'approbation de Santé Canada pour son Illuccix, un kit pour la préparation de l'injection de gallium (68Ga) gozetotide. Le produit peut être utilisé dans la stadification et la re-stadification du cancer de la prostate à risque intermédiaire et élevé et dans la localisation du tissu tumoral dans le cancer de la prostate récurrent. Illuccix a été le premier agent d'imagerie TEP PSMA à obtenir une approbation réglementaire au Canada. Santé Canada a été le troisième organisme de réglementation au monde à approuver Illuccix, qui est disponible dans le commerce en Australie et aux États-Unis.
- En décembre 2021, GE Healthcare et Minerva Imaging ont conclu un partenariat stratégique pour accélérer le lancement commercial du radionucléide ciblé thérapeutiques (théranostiques). La thérapie par radionucléides est une forme de médecine de précision dans laquelle une substance radioactive est administrée par la circulation sanguine pour cibler les cellules cancéreuses et les irradier spécifiquement. Cela aide à réduire les effets secondaires potentiels par rapport aux thérapies anticancéreuses traditionnelles.
Profils d'entreprise - Marché de la théranostique radiopharmaceutique
- Bayer AG
- GE HealthCare Technologies Inc.
- Curium
- Lantheus Medical Imaging, Inc.
- Telix Pharmaceuticals Ltd.
- Cardinal Health Inc
- Advanced Accelerator Applications SA
- Jubilant Radiopharma
- Théragnostique
- NuView Life Sciences
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Radiopharmaceuticals are radioisotopes that are bound to biological molecules that target specific tissues, organs, or cells within the human body. Radioisotopes emitting gamma rays are useful for diagnostic imaging where the radiation escapes the body. Nuclear medicine imaging generally utilizes radioactive isotopes attached to specific molecules to examine biological processes, such as disease pathophysiology. Every radiopharmaceutical is designed to travel to a specific location in the body, and as soon as it reaches the site, it releases radioactive substances that kill the tumor cells. Radiopharmaceuticals can target various malignancies such as prostate cancer, heart disease, thyroid cancer, and others. These drugs can also be used as both therapies and diagnostics, known as 'theranostics’. In theranostics, radiopharmaceuticals are used for therapeutic and diagnostic purposes by targeting one specific tumor receptor.
Key factors that are driving the growth of this market are rising incidence of cancer and the growing application in the treatment of cardiovascular disorders are expected to boost the market growth for the radiopharmaceutical theranostics over the years.
The CAGR value of the biopharmaceuticals market during the forecasted period of 2022-2028 is 11.3%.
The positron emission tomography (PET) tracers segment held the largest share of the market in the global radiopharmaceutical theranostics market and held the largest market share of 44.76% in 2022.
The Lutetium (Lu) 177 segment dominated the global radiopharmaceutical theranostics market and held the largest market share of 24.34% in 2022.
The cyclotrons segment dominated the global radiopharmaceutical theranostics market and held the largest market share of 60.42% in 2022.
Answer: - The targeted therapeutic [Rx] segment dominated the global radiopharmaceutical theranostics market and held the largest market share of 63.28% in 2022.
The oncology segment dominated the global radiopharmaceutical theranostics market and held the largest market share of 62.18% in 2022.
The hospitals segment dominated the global radiopharmaceutical theranostics market and held the largest market share of 36.28% in 2022.
The radiopharmaceutical theranostics market majorly consists of the players such Bayer AG, GE HealthCare Technologies Inc, Curium, Lantheus Medical Imaging, Inc.; Telix Pharmaceuticals Ltd.; Cardinal Health Inc, Advanced Accelerator Applications S.A.; Jubilant Radiopharma, Theragnostics, and NuView Life Sciences amongst others.
The List of Companies - Radiopharmaceutical Theranostics Market
- Bayer AG
- GE HealthCare Technologies Inc
- Curium
- Lantheus Medical Imaging, Inc.
- Telix Pharmaceuticals Ltd.
- Cardinal Health Inc
- Advanced Accelerator Applications S.A.
- Jubilant Radiopharma
- Theragnostics
- NuView Life Sciences
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Mar 2023
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Mar 2023
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Mar 2023
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Mar 2023
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Mar 2023
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Mar 2023
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Mar 2023
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Mar 2023
Hyperpigmentation Disorder Treatment Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment Type (Cosmeceutical, Light or Laser Therapy, Microdermabrasion, Chemical Peels, Cryotherapy, and Others), Condition (Melasma, Solar Lentigines, Post-Inflammatory Hyperpigmentation, and Others), End User (Hospitals, Dermatology Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)